Get the tools used by (smart)
2
investors.
Get Started
Search
SP500 
2.1%
DOW 
1.6%
FTSE 100 
1.1%
NIKKEI 
0.7%
OIL 
0.9%
GOLD 
0.0%
Sign In
Watchlists
Ideas
Screener
Data Explorer
Charts
Saved Work
Collapse
Inozyme Pharma Inc
NASDAQGS:INZY
United States / Healthcare / Biotechnology
Currency
$
+ Add Watchlist
Overview
Dividends
Earnings
Models
Financials
Compare
Health
Charts
Income Statement
Balance Sheet
Cash Flow Statement
EBITDA Reconciliation
Net Income Reconciliation
Forecasts
Valuation Ratios
Income Statement
Fiscal Years
Fiscal Half
Fiscal Quarters
Year To Date
Latest Twelve Months
Fiscal Years
Ascending
Descending
Ascending
3 Years
5 Years
10 Years
5 Years
Millions
Billions
Thousands
Ones
Millions
Standard Size
Common Size
Growth Rate
Standard Size
2020-05-31
FY-4
2021-05-31
FY-3
2022-05-31
FY-2
2023-05-31
FY-1
2024-05-31
FY
Revenue
7,085.1
7,116.3
7,854.5
8,815.8
9,596.6
Revenue Growth (YoY)
2.8%
0.4%
10.4%
12.2%
8.9%
Cost of Revenues
-3,851.4
-3,801.7
-4,222.2
-4,642.4
-4,910.2
Gross Profit
3,233.7
3,314.7
3,632.2
4,173.4
4,686.4
Gross Profit Margin
45.6%
46.6%
46.2%
47.3%
48.8%
R&D Expenses
-21.5
-22.3
-23.5
-24.5
-26.6
Selling, General & Admin Expenses
-2,061.8
-1,924.0
-2,044.9
-2,370.7
-2,617.8
Other Inc / (Exp)
12.3
17.2
23.5
24.5
26.6
Operating Expenses
-2,071.1
-1,929.2
-2,044.9
-2,370.7
-2,617.8
Operating Income
1,162.7
1,385.5
1,587.4
1,802.7
2,068.6
Net Interest Expenses
-104.4
-97.7
-88.6
-109.5
-95.0
EBT, Incl. Unusual Items
1,058.3
1,287.7
1,498.8
1,693.1
1,973.6
Earnings of Discontinued Ops.
-0.3
-
-
-
-
Income Tax Expense
-181.9
-176.8
-263.0
-345.1
-402.0
Net Income to Company
876.0
1,111.0
1,235.8
1,348.0
1,571.6
Minority Interest in Earnings
-
-
-
-
-
Net Income to Stockholders
876.0
1,111.0
1,235.8
1,348.0
1,571.6
Preferred Dividends & Other Adj.
-7.8
-7.6
-6.1
-5.5
-5.9
Net Income to Common Excl Extra Items
868.2
1,103.3
1,229.6
1,342.5
1,565.7
Basic EPS (Cont. Ops)
2.09
2.63
2.98
3.30
3.85
Diluted EPS (Cont. Ops)
2.03
2.56
2.91
3.25
3.79
Weighted Average Basic Shares Out.
415.3
419.5
412.7
406.6
406.6
Weighted Average Diluted Shares Out.
428.0
430.8
422.1
413.5
413.5
EBITDA
1,451.7
1,673.2
1,876.2
2,092.5
2,383.0
EBIT
1,171.9
1,390.6
1,587.4
1,802.7
2,068.6
Revenue (Reported)
7,085.1
7,116.3
7,854.5
8,815.8
9,596.6
Operating Income (Reported)
1,162.7
1,385.5
1,587.4
1,802.7
2,068.6
Operating Income (Adjusted)
1,171.9
1,390.6
1,587.4
1,802.7
2,068.6
FY-4
FY-3
FY-2
FY-1
FY
0
1
2
3
4
presentment in Millions except per share data. All rights reserved.
Terms Of Use
1